Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: A mixed methods study

AIDS Patient Care and STDs

Volumn 26, Issue 2, 2012, Pages 87-94

  Brooks, Ronald A ^a   Landovitz, Raphael J ^b   Kaplan, Rachel L ^a   Lieber, Eli ^a   Lee, Sung Jae ^c   Barkley, Thomas W ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY; ARTICLE; BISEXUAL MALE; CLINICAL ARTICLE; CONDOM; CONTROL STRATEGY; COUNSELING; ETHNIC GROUP; HEALTH SURVEY; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTERVIEW; MALE; MALE HOMOSEXUAL; PROPHYLAXIS; QUALITATIVE ANALYSIS; RACE; RISK REDUCTION; SEXUAL BEHAVIOR;

ADULT; ANTI-HIV AGENTS; BISEXUALITY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SURVEYS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MOTIVATION; PRIMARY PREVENTION; RISK-TAKING; SEXUAL BEHAVIOR; SEXUAL PARTNERS;

EID: 84863064778     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.0283     Document Type: Article

References (25)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compare with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795-802. (Pubitemid 29415583)
2. Cardo D, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care worker after percutaneous exposure. N Engl J Med 1997;337:1485-1490. (Pubitemid 27495773)
3. Center for Disease Control and Prevention (CDC). Antiretroviral postexposure prophylaxis after sexual, injectiondrug use, or other nonoccupational exposure to HIV in the United States. MMWR Morb Mortal Wkly Rep 2005;54: 1-20.
4. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLOS Med 2008;5:e28:0291-0299.
5. Van Rompay KK, McChesney MB, Aguirre NL, et al. Two low doses of tenofovir protect new-born macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184:429-438. (Pubitemid 32718506)
6. Grant R.M, Lama JR, Anderson PL, et al. Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men. N Engl J Med 2010;363:2587-2599.
7. Baeten JM, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: The Partners PrEP Study [Abstract MOAX0106]. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy: July 17-20, 2011.
8. Thigpen MC, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: Results from the TDF2 study [Abstract WELBC01]. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011). Rome, Italy: July 17-20, 2011.
9. Barash EA, Golden M. Awareness and use of HIV preexposure prophylaxis among attendees on a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDs 2010;24:689-691.
10. Kellerman SE, Hutchinson AB, Begley EL, Boyett BC, Clark HA, Sullivan P. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gaypride events. J Acquir Immune Defic Syndr 2006;43:376-377. (Pubitemid 44674022)
11. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008;47:241-247. (Pubitemid 351172193)
12. Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: Limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr 2009;50:77-83.
13. Nodin N, Carballo-Diéguez A, Ventuneac AM, Balan IC, Remien R. Knowledge and acceptability of alternative HIV prevention bio-medical products among MSM who bareback. AIDS Care 2008;20:106-115. (Pubitemid 351264545)
14. Paxton L, Hope T, Jaffe HW. Pre-exposure prophylaxis for HIV infection: What if it works? Lancet 2007;370:89-93. (Pubitemid 47033881)
15. Brooks RA, Kaplan RL, Lieber E, et al. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIVserodiscordant male relationships. AIDS Care 2011;23:1136-1145.
16. Anderson P, Lama J, Buchbinder S, et al. Interpreting detection rates of intracellular FTC-TP and TFV-DP: The iPrEx trial [Abstract 96LB]. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, Massachusetts: February 27 to March 3, 2011.
17. Grant R, Lama J, Glidden D, et al. Pre-exposure chemoprophylaxis for prevention of HIV among trans-women and MSM: iPrEx study [Abstract 92]. 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011). Boston, MA: February 27 to March 3, 2011.
18. SocioCultural Research Consultants, LLC. 2011, Dedoose version 3.1. www.dedoose.com (Last accessed October 11, 2011).
19. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77-101.
20. Strauss A, Corbin J. Basics of Qualitative Research. Thousand Oaks, CA: Sage, 1998.
21. Marks G, Millett G A, Bingham T, et al. Prevalence and protective value of serosorting and strategic positioning among Black and Latino men who have sex with men. Sex Transm Dis 2010;37:325-327.
22. Parsons JT, Schrimshaw EW, Wolitski RJ, et al. Sexual harm reduction practices of HIV-seropositive gay and bisexual men: Serosorting, strategic positioning, and withdrawal before ejaculation. AIDS 2005;19(Suppl 1):S13-25.
23. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost effectiveness. AIDS 2008;22:1829-1839.
24. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: Impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-815.
25. Cohen M S, Chen Y Q, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.